SLAMF8 can predict prognosis of pan-cancer and the immunotherapy response effectivity of gastric cancer

• DOI: 10.18632/aging.205850
• Publication Date: 2024-05-22T16:17:12Z
• Authors: Guangyao Li; Qijiao Li; Miaomiao Ping; Ziying Jiao; Xingxing Wang; Juan Cheng; Jizheng Guo; Ya Cheng
• Keywords: Microsatellite Instability; Cancer Immunotherapy; Immune checkpoint

SLAMF8, the eighth member of Signaling Lymphocytic Activation Molecule Family (SLAMF), functions in regulation development and activity diverse immune cells as a costimulatory receptor within SLAMF family. Studies had revealed that SLAMF8 is expressed higher several autoimmune inflammation diseases tumors. Nevertheless, connection between pan-cancer remains undisclosed. The research investigated correlation various factors including microenvironment, microsatellite instability, novel antigen, gene mutation, regulatory factors, blockade TMB, or molecular subtypes verse cancer types. Immunohistochemistry was ultimately employed to validate presence tumor types hepatocellular carcinoma, prostate adenocarcinoma, kidney renal clear cell carcinoma. Furthermore, relationship expression therapeutic efficacy PD1 agent, Sintilimab, treatment gastric validated. result differential analysis suggested over-expressed compared with paracancerous tissues. survival indicated overall prognosis different cancers, where levels were found be significantly linked unfavorable outcomes patients but favorable outcome immunotherapy cancer. Significant correlations observed tumorigenesis, metabolism, immunity. As result, may become an important prognostic biomarker majority tumors hopeful target for against